von Mylan war als Labs oder N.V. immer in Canonsburg Pennsylvania und ist der Generikahersteller im Nasdaq 100. Wäre schade, wenn die Performance im Börsenspiel wegen der Umfimierung verloren gehen würde. .. Mylan N.V. Aktualisieren ISIN NL0011031208 | WKN A14NYH fallend 63,76 ? -3,37% 14.04.2015 19:14 -2,22 ? Adresse:
1000 Mylan Boulevard, Canonsburg, Pennsylvania 15317, USA Telefon: +1-724-514-1800 Telefax: Internet: Zur Unternehmenshomepage
Mylan Laboratories Inc. - Company Profile, Information, Business Description, History, Background Information on Mylan Laboratories Inc.
1500 Corporate Drive, Suite 400 Canonsburg, Pennsylvania 15317-8580 U.S.A.
Company Perspectives:
By focusing on key principles of quality and integrity, Mylan has established a position of leadership in the pharmaceutical industry; in fact, today, Mylan is the #1 most widely dispensed line of pharmaceuticals in America. The company's success can be attributed to outstanding management, dedicated employees, and upholding its founding corporate motto: "We either do it right or we don't do it at all." History of Mylan Laboratories Inc.
Mylan Laboratories Inc. is one of the leading manufacturers of generic drugs in the United States. The firm produces and markets numerous generic and proprietary (brand-name) drugs, with the sale of generics providing 80 percent of total revenues. Mylan's generic operations are conducted through two principal subsidiaries, Mylan Pharmaceuticals Inc. and UDL Laboratories, Inc.; while the company's branded segment operates through Bertek Pharmaceuticals Inc. and Mylan Technologies Inc., with Bertek focusing on three therapeutic areas: dermatology, neurology, and cardiology. In addition, Mylan is involved in a 50-50 joint venture with Watson Pharmaceuticals, Inc. called Somerset Pharmaceuticals, Inc., whose single commercial product is Eldepryl, a treatment for Parkinson's disease. Mylan made its mark in the pharmaceutical industry as a manufacturer of generic drugs, or those pharmaceutical products no longer protected by patents. From the manufacture of generic drugs, the company branched out into brand-name pharmaceuticals, introducing its first proprietary drug, Maxzide, in 1984. Acquisitions completed from the late 1980s through the mid-1990s brought Mylan into other market niches, including anti-Parkinson's disease medications and transdermal drug delivery systems. During the early 2000s, the company's operations included research and development laboratories and manufacturing facilities in West Virginia, Puerto Rico, Texas, Vermont, and Illinois, and a distribution center in North Carolina.
Read more: http://www.referenceforbusiness.com/history2/71/...html#ixzz3XKGj7rcX
|